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Prognostic factors affecting the survival of patients
with multiple myeloma
A retrospective analysis of 86 patients
B. L. RAPOPORT, H. C. FALKSON, G. FALKSON
Summary
A retrospective analysis of data concerning 86 patients with
multiple myeloma was carried out in order to evaluate factors
affecting survival. The overall median survival was 621 days.
In a univariate analysis the follOWing factors were signifi-
cantly associated with poor survival: serum creatinine ~ 150
mmolll, haemoglobin < 11 g/dl and serum calcium values>
2,75 mmol/l; and Eastern Cooperative Oncology Group per-
formance status 3 - 4. However, age, sex, Durie and Salmon
staging, lytic lesions, serum immunoglobulin concentration,
urine Bence Jones protein, percentage of plasma cells in the
bone marrow, proteinuria, and type of chemotherapy given
were not significantly associated with survival. A strong pre-
diction of survival was found by grouping the serum creatinine
and haemoglobin levels of patients at presentation.
S AIr Med J 1991; 79: 65-67.
Multiple myeloma is a chronic disease of the haemopoietic
system characterised by clonal proliferation of B cells. The
median survival of patients with multiple myeloma was
approximately 6 months. However, with the introduction of
chemotherapy in the management of this disease survival has
increased to approximately 30 months. I Staging is of practical
value and plays an important role in therapeutic decisions in
the management of malignant disease; this is especially so in
malignant disease of the haemopoietic system. It has been
suggested that staging could be utilised in myeloma when
making therapeutic deci~ions, and also for adding prognostic
insight. Durie and Salmon2 proposed a clinical staging where
the myeloma cell mass was assessed by the paraprotein level in
serum and urine, the extent of bone lesions, and the haemo-
globin level and serum calcium values. Other investigators
utilise an !lPproach where a combination of presenting features
are correlated with survival. J-9 We analysed the data from 86
patients treated with various protocols to determine the signifi-
cance of clinical features at presentation in relation to survival.
Patients and methods
Records of 86 previously untreated patients with multiple
myeloma were analysed; the patients were all whi~e, from .a
single institution and were seen between 1966 and 1986. Therr
median age was 60 years (range 31 - 77 years), and 5.1 were
men. The diagnosis of multiple myelomawas made usmg the
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Chronic Leukemia-Myeloma Task Force criteria. IO Using the
Durie and Salmon2 staging, 8 patients had stage I disease, 26
stage 11 and 52 stage III disease. Performance status (PS) was
judged according to Eastern Cooperative Oncology Group
(ECOG) criteria: ll 48 patients had a good performance status
(PS 1 - 2; Karnofsky 90 - 50%), and in 38 patients the PS was
3 - 4 (Kamofsky 40 - 10%). .
The following treatments were given: 49 patients received
melphalan and prednisone, 17 received carmustine and predni-
sone, 10 received a combination of carmustine + melphalan +
vincristine + cyclophosphamide + prednisone, 4 received
melphalan + carmustine + cyclophosphamide, 3 received
melphalan + carmustine + prednisone and 3 received lomus-
tine + prednisone. Treatments were allocated according to the
randomised trials ongoing at the institution. If the patient did
not fulfil the eligibility criteria of the relevant protocol, treat-
ment was given according to the investigator's discretion.
In addition to history and clinical examination, the following
investigations were performed initially and at 6 - 8-week
intervals: full blood count, serum chemistry, serum and urine
eletrophoresis, serum M-<:omponents and immunoglobulin
quantification, bone marrow aspiration, and skeletal radio-
graphy. Other r-arameters, such as cell-labelling index,I2 f32-
microglobulin, I -14 degree of infiltration on the bone marrow
trephine biopsy,I5 cytogenetics and immunophenotype, light-
chain excretion, and lactic dehydrogenase level, recently recog-
nised to be of prognostic value, were not included in the
analysis because they were available in only a small proportion
of patients.
Statistical methods. The Kaplan and Meier life-table
method was used for analysing survival. 16 Significance between
curves was calculated using the Mantel-Cox and Breslow
tests. 17 A Cox multivariate regression hazards analysis was
done to assess the combined effect of the different clinical
factors on survival. IS All statistical tests were done by SAS and
BMDP computer programs.
(Results
The following parameters were found to be of prognostic
significance: renal function as measured by serum creatinine
value; hypercalcaemia; anaemia; hypo-albuminaemia; and
ECOG PS. A multivariate regression model showed the signi-
ficance as follows: serum creatinine level (P = 0,0002); serum
calcium level (P = 0,01); serum albumin level (P = 0,03); and
haemoglobin value (P = 0,05). In this model the PS lost its
significance.
Renal function
Renal function, judged by serum creatinme values, was the
most important prognostic parameter in this group of patients.
Patients with a normal serum creatinine level had a median
survival of 1011 days, while the median survival of those with
abnortnal serum creatinine values was 216 days; this is statis-













Fig. 3. Survival of patients according to serum calcium v.alues
(normocalcaemic = .-.; hypercalcaemic = ...... ).
tically significant (P = 0,00(01). The survival of patients with
a serum creatinine level < ISO }.Lmol/l compared with the
survival of those with a serum creatinine level ~ ISO }.Lmol/l is







group had a median survival of 222 days v. 889 days of those
who were normo-albuminaemic at presentation. This difference





Fig. 1. Survival of patients according to serum creatinine values











In a univariate analysis the PS was of significant prognostic
importance. The median survival of patients with a good PS
36 48
MONTHS
Fig. 4. Survival of patients according to serum albumin values












Anaemia was another variable with prognostic significance.
Patients with a haemoglobin value ~ 11 gIdl had a median
survival of 885 days, which was significantly better than the
median survival of 209 days for patients with a haemoglobin
value < 11 gldl (P = 0,0001) (Fig. 2).
36 48
MONTHS
Fig. 2. Survival of patients according to haemoglobin values,
( ...... = haemoglobin < 11 g/dl; .-. = haemoglobin;;" 11
g/dl).
Hypercalcaemia
Thirty per cent of patients in this series presented with a
raised serum calcium level. This subgroup of patients had a
median survival of 346 days, which was significantly poorer
than the median survival of 706 days among the patients who






Fig. 5. Survival of patients according to ECOG PS (.-. =PS 1
and 2; ...... = PS 3 and 4).
Hypo-albuminaemia
Hypo-albuminaemia was another prognostic variable signi-
ficantly associated with poor survival. The.hypo-albuminaemic
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was 662 days. This was significantly bener than the 341 day
median survival of those with a poor PS (P = 0,01) (Fig. 5).
Fig. 6. Comparison of survival according to the Durie and
Salmon 2 (right) staging system and haemoglobin and creatinine
levels (left) combined.
Durie and Salmon staging
The pretreatment stage of each patient was assessed accord-
ing to the Durie and Salmon classification.2 Difference in
survival for the three stages was not statistically significant (P
= 0,79). Median survival of 8 patients with stage I disease was
1 178 days, of 26 patients with stage 11 disease 620 days, and
of 52 patients with stage III disease 621 days (Fig. 6).
concentration and the clinical PS; they divided patients into
those with a good, intermediate and poor prognosis. We found
that serum creatinine value is more accurate for assessing renal
function than serum urea. Flucruation of the serum urea level
occurs during dehydration, a complication often encountered
in patients with multiple myeloma.
The importance of PS as a predictive discriminant of survival
was documented by the BMRC series as well as the Argentine
Group for the Treatment of Acute Leukemia (GATLA).s,8
GATLA analysed 410 patients treated on two different pro-
tocols; the most important predictors of survival were impaired
PS and bone marrow inflltration with more than 40% plasma
cells.
The importance of estimating the pretreatment tumour cell
mass was previously demonstrated by Salmon and Smith19 and
confirmed by Woodruff er ai. 20 This mathematical calculation
was based on the rate of paraprotein production by the
myeloma cells on a culture media. In our patients paraprotein
levels did not correlate with survival.
In the analysis of our data the staging system of Durie and
Salmon2 was not of statistically significant prognostic impor-
tance.
In conclusion, we found that presenting features can be
practically utilised and are of better prognostic value in patients
with multiple myeloma than the staging system proposed by
Durie and Salmon.2 This finding agrees with that of the






Haemoglobin and creatinine values combined
A combination of the haemoglobin and serum creatinine
values recorded at presentation was compared in three groups.
The first group had.a haemoglobin value ~ 11 g/dl and a
serum creatinine level ~ 149 ~moVl, the second group had a
haemoglobin value < 11 g/dl and a serum creatinine level ~
150 mmoVl; the third group of patients were those who had
either a normal haemoglobin value with an abnormal serum
creatinine level or an abnormal haemoglobin value with a
normal serum creatinine level. The median survivals were 925
days, 109 days and 360 days respectively. The survival curves
are shown in Fig. 6 and demonstrate a significant difference
between the three groups (P = 0,00(01).
Other parameters
The following parameters did not significantly affect survival:
age; sex; number of lytic lesions; uric acid levels; paraprotein
type; paraprotein levels; Hence Jones proteinuria; proteinuria
> 1 g/24 h; and the type of cytostatic treatment administered. -
Discussion
This study was undertaken in order to analyse the prognostic
significance of the most common features and complications of
multiple myeloma. It demonstrated the importance of evalua-
ting presenting features in relation to patient survival. Analysis
of data shows that several clinical parameters are associated
with poor prognosis. Clinical features with prognostic signifi-
cance were, in order of importance: abnormal renal function;
anaemia; hypo-albuminaemia; hypercalcaemia; and impaired
PS. However, in a Cox multivariate regression model of
clinical features, the PS lost its significance.
In an analysis of 485 patients with multiple myeloma the
British Medical Research Council's (BMRC) Working Party
on Leukaemia in Adults reported similar results. 3 These
investigators found that the three major determinants of prog-
nosis were the blood urea concentration, the haemoglobin
This srudy was supported in part by a grant from the National
Cancer Association of South Africa and the Freda and David
Becker Trust.
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